Chronic idiopathic constipation is a serious health condition that affects adults with no apparent reason.
Synergy Pharmaceuticals Inc. was happy to announce on Sunday that the U.S. Food and Drugs Administration (FDA) gave green light to their new medicine to appear on the market. This is about Trulance which promises to help adults overcome their chronic idiopathic constipation. The world of science is still unaware of the reason people get this condition. Its main symptoms are bowel movement at infrequent times and stool problems.
Constipation is a common experience that happens to almost all people. It is normal for everyone to go through these situations several times. However, when this condition happens on a regular basis, it might degenerate into a chronic illness. Chronic constipation has no identifiable cause that could have triggered it. This is why it is also called idiopathic, which means that there is no apparent reason for this condition to appear.
Julie Beitz, the director of the Office of Drug Evaluation III at FDA, stated that each patient needs a different treatment. There is no panacea to treat them all in the same measure. The introduction of Trulance on the market offers patients a new type of treatment to help them with their chronic idiopathic constipation.
Trulance medication is actually the first of its kind. It has the capacity to copy the function of uroguanylin, which is an endogenous gastrointestinal peptide specific only to humans. Its main role is believed to be that of stimulating the secretion of the necessary fluid that leads to stool consistency. Once this peptide received extra support from outside, the bowel movement will become regular. This is how Trulance can save people from chronic idiopathic constipation.
Dr. Gary S. Jacob, the CEO of Synergy Pharmaceuticals Inc. was thrilled to see the approval of FDA for their new treatment. He stated that this innovative medication is just what a market with great demand but few options of offers needed. Trulance has successfully passed one of the most in-depth clinical trials till this day. The testing stage required a Phase 3 CIC where more than 2,600 patients participated. The studies of Trulance had two randomized cycles in double-blind 12 weeks, placebo-controlled trials.
The FDA was content with the results of the trials. Participants showed significant improvement in their condition. The effects were that of bowel movement readjustment and stool consistency. However, such treatment shouldn’t be applied to people that are not of age. The trials didn’t involve persons younger than 18 years, which means that there is not known how Trulance would work on them.
Image source: 1
Share this:
